QT prolongation risk factors and a monitoring strategy in rifampicin-resistant tuberculosis: Findings from the STREAM Stage 2 trial
Gareth Hughes, Elena Frangou, Henry Bern, Meera Gurumurthy et autres
Treatment of rifampicin-resistant tuberculosis (RR-TB) involves drugs that can prolong the QT interval. There is limited data on risk factors and the level of cardiac monitoring required. We analysed STREAM Stage 2 data to address these issues. A post-hoc analysis was undertaken …
gb, mn, fr, tw (code pays fourni par la source)
0 citations
PLOS Global Public Health